Breo Ellipta Lawsuit & Settlements: Everything You Need to Know

What Is Breo Ellipta?

Breo Ellipta is a once-daily prescription inhaler approved by the U.S. Food and Drug Administration for managing chronic obstructive pulmonary disease (COPD) and asthma. It combines two active ingredients: fluticasone furoate (an anti-inflammatory corticosteroid) and vilanterol trifenate (a long-acting bronchodilator). Together, they reduce airway inflammation and keep the breathing passages open.

The FDA first approved Breo Ellipta for COPD in May 2013, then expanded its label to include asthma in April 2015 — backed by clinical trials involving more than 7,700 patients.

How to Use Breo Ellipta

Using Breo Ellipta correctly matters for it to work. You open the cover, slide the mouthpiece, exhale fully away from the inhaler, then breathe in steadily and deeply through the mouthpiece. Hold your breath for about 3–4 seconds, then exhale slowly. It is a dry-powder inhaler, so you do not shake it. One inhalation once a day — same time each day — is the standard dose.

Breo Ellipta Side Effects

Like all medications, Breo Ellipta carries a risk of side effects. Common ones include upper respiratory tract infection, headache, oral thrush (fungal infection in the mouth), and nasopharyngitis. More serious reported effects — which form the basis of several individual injury claims — include:

• Pneumonia (especially in patients with COPD)
• Bone fractures (from long-term corticosteroid use)
• Heart rhythm abnormalities (atrial fibrillation)
• Adrenal suppression with prolonged use

Patients who experienced these effects and felt they were not adequately warned have filed personal injury lawsuits against the manufacturer.

Who Is GlaxoSmithKline (GSK)?

GlaxoSmithKline (GSK) is one of the world’s largest pharmaceutical companies, headquartered in London, UK. It develops and sells medicines, vaccines, and consumer healthcare products globally. Breo Ellipta was developed as a joint venture between GSK and Theravance Biopharma. GSK serves as the primary manufacturer and holds the product license. With annual revenues exceeding £30 billion, GSK is no stranger to large-scale litigation — patent disputes and product liability claims are a standard part of operating at that scale.

The Breo Ellipta Lawsuit: What Actually Happened?

There are two distinct legal threads running through the Breo Ellipta lawsuit story:

1. The Patent Infringement Case (Vectura vs. GSK)

In 2016, Vectura Limited — a British pharmaceutical technology company — sued GSK, alleging that the Ellipta inhaler range, including Breo Ellipta, Anoro Ellipta, and Incruse Ellipta, infringed its U.S. Patent No. 8,303,991. That patent covered the production of “composite active particles” designed for pulmonary delivery, specifically the use of magnesium stearate as an additive to improve how medication disperses in the lungs.

Vectura argued GSK incorporated this patented process into its dry-powder inhaler technology without authorization.

2. Individual Injury Claims

Separately, a number of patients filed individual lawsuits claiming Breo Ellipta caused serious harm — including pneumonia and cardiovascular complications — and that the warnings on the product were insufficient.

Breo Ellipta Settlement Timeline

Here’s a clear timeline of how the Breo Ellipta lawsuit unfolded:

• May 2013 — FDA approves Breo Ellipta for COPD
• April 2015 — FDA expands approval to include asthma treatment
• 2016 — Vectura Limited files patent infringement lawsuit against GSK in U.S. District Court for the District of Delaware
• May 2019 — After a five-day trial, a federal jury finds GSK willfully infringed Vectura’s ‘991 patent and awards $89,712,069 in damages (calculated as a 3% royalty on $2.99 billion in accused product sales)
• November 19, 2020 — The U.S. Court of Appeals for the Federal Circuit unanimously affirms the lower court verdict, upholding the $89.7 million award along with pre- and post-judgment interest
• 2021 onwards — Philip Morris International acquires Vectura Group, drawing media attention; individual injury cases continue in various stages of litigation

Why Did GlaxoSmithKline Pay the Settlement?

The short answer: because two separate courts said they had to.

Vectura successfully proved that GSK used its patented method for combining magnesium stearate with active drug particles — a process that makes dry-powder inhalers more effective. The jury in Delaware found this infringement willful, meaning GSK likely knew about the patent and proceeded anyway. The Federal Circuit’s affirmation in November 2020 closed most routes for appeal, making the nearly $90 million payout unavoidable.

For context: $89.7 million was calculated as just 3% of the $2.99 billion GSK earned from selling the infringing Ellipta inhaler products. For a company of GSK’s size, the royalty rate itself was modest — but the scale of sales made the final number large.

Breo Ellipta Lawsuit Update (2025–2026)

The core patent case between Vectura and GSK is resolved. The $89.7 million verdict stands. However, individual patient injury lawsuits — based on allegations of inadequate warnings about pneumonia risk and other serious side effects — remain active in various U.S. courts. No large class-action settlement has been announced as of early 2026. Patients who believe they suffered harm from Breo Ellipta should consult a licensed attorney to understand their individual options.

It is also worth noting that Breo Ellipta remains available on the market. The patent case did not result in a recall or withdrawal — it was a business dispute over intellectual property, not a product safety ruling.

Disclaimer: This article is intended for general informational purposes only and does not constitute legal, medical, or financial advice. The information presented here is based on publicly available court records, FDA documentation, and news sources at the time of writing (April 2026). Laws, litigation outcomes, and medical guidance can change — always consult a licensed attorney for legal questions and a qualified healthcare professional for medical decisions. The author and publisher assume no liability for actions taken based on the content of this article.